Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Polar Capital Holdings Plc

Polar Capital Holdings Plc decreased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 37.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 627,036 shares of the biopharmaceutical company's stock after selling 375,000 shares during the quarter. Polar Capital Holdings Plc owned approximately 1.10% of Agios Pharmaceuticals worth $20,604,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Envestnet Asset Management Inc. boosted its position in Agios Pharmaceuticals by 3.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock worth $815,000 after acquiring an additional 795 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter worth about $33,000. Franklin Resources Inc. acquired a new position in Agios Pharmaceuticals during the third quarter worth about $1,499,000. Vanguard Group Inc. boosted its position in Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after acquiring an additional 85,339 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Agios Pharmaceuticals by 48.8% during the fourth quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company's stock worth $8,725,000 after acquiring an additional 87,089 shares during the last quarter.

Analysts Set New Price Targets

AGIO has been the topic of several recent analyst reports. Scotiabank decreased their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, May 10th. Finally, HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $56.00.

Insider Activity

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now directly owns 149,220 shares in the company, valued at $3,864,798. This represents a 4.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $28.26 on Friday. The company's 50 day simple moving average is $28.87 and its 200-day simple moving average is $36.81. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 2.49 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The business had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.